Central Nervous System Embryonal Tumor — Trials

Central Nervous System Embryonal Tumor — Trials · CancerIndex

Clinical trials

Registered studies

240 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 72
Recruiting: 33
Ph III recruiting: 2
Growth YoY: —
Industry share: 4%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (32)

clinicaltrialsPublishedShowing 51–100 of 240 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03874455	Tazemetostat Expanded Access Program for Adults With Solid Tumors	no longer available	—	—	Epizyme, Inc.INDUSTRY	0	Jul 2, 2026	clinicaltrials
NCT04195555	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)	active not recruiting	Phase 2	3	National Cancer Institute (NCI)NIH	3	Jul 1, 2026	clinicaltrials